Trazodone is primarily indicated for the treatment of major depressive disorder (MDD). Its antidepressant effect stems from inhibition of serotonin reuptake and antagonism at specific serotonin receptor subtypes, which can help improve mood, appetite, and energy in affected patients. Clinicians also commonly prescribe trazodone off-label for insomnia because its sedative properties—mediated largely through histamine and alpha-adrenergic receptor blockade—can help with sleep initiation and maintenance when traditional hypnotics are unsuitable or contraindicated.
Beyond depression and sleep disturbances, trazodone is sometimes used adjunctively in anxiety disorders, chronic pain syndromes, and certain behavioral problems in older adults. Evidence varies by indication; therefore, benefit-risk assessment and individualized care plans are essential. Trazodone may be preferred in patients who need both an antidepressant effect and improved sleep, provided safety considerations are addressed.
Dosing depends on the indication, formulation, and patient factors such as age, comorbidities, and concomitant medications. For depression in adults, immediate-release trazodone is often started at 150 mg daily, divided into multiple doses, and titrated by 50 mg every three to four days as tolerated; effective ranges frequently fall between 150–400 mg daily. Extended-release formulations may be initiated at lower once-daily doses tailored per product labeling.
For insomnia, lower nightly doses—commonly 25–100 mg—are used to harness sedative effects while limiting daytime sedation. When using trazodone for sleep, take it shortly before bedtime. Elderly patients generally require lower starting doses (e.g., 25–50 mg at night) because of increased sensitivity to orthostatic hypotension and sedation. Always follow prescriber instructions; dose adjustments may be necessary for hepatic impairment and when combined with strong CYP450 inhibitors.
Trazodone carries several important precautions. Patients should be monitored for increased suicidal ideation, especially children, adolescents, and young adults during the initial months of therapy or when doses change. Orthostatic hypotension and syncope can occur, particularly during dose escalation—counsel patients to rise slowly from sitting or lying positions.
Trazodone can contribute to serotonin syndrome when used with other serotonergic agents (SSRIs, SNRIs, triptans, MAOIs, certain herbal supplements like St. John’s wort). Symptoms range from mild (shivering, diarrhea) to life-threatening (hyperthermia, muscle rigidity). Rare but serious adverse events include priapism—an emergency requiring immediate medical attention—and cardiac conduction changes, including QT prolongation, especially in patients with existing cardiac disease or electrolyte abnormalities.
Absolute contraindications include a known hypersensitivity to trazodone or any component of the formulation. Concomitant or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of severe, potentially fatal reactions such as serotonin syndrome and hypertensive crises. Caution is warranted when combining trazodone with other central nervous system depressants.
Trazodone is not recommended for pediatric use in children under 18 for depression without specialist oversight; safety and efficacy have not been established for many pediatric populations. In pregnancy, risks and benefits should be weighed carefully—treatment decisions should be made collaboratively between patient and clinician.
Common side effects include drowsiness, dizziness, dry mouth, headache, blurred vision, constipation, and nausea. Sedation is one of the most frequently reported effects and is the reason trazodone is often used for insomnia. Many side effects are dose-related and may improve with time or dose adjustments.
Less common but clinically significant adverse events include orthostatic hypotension, cardiac arrhythmias including QT prolongation, hyponatremia (particularly in older adults), and priapism, which although rare, requires urgent medical evaluation. If any severe or persistent side effects occur—such as fainting, chest pain, severe dizziness, or prolonged erection—seek immediate medical care.
Trazodone has important drug–drug interactions to consider. Concomitant use with MAOIs is contraindicated. Combining trazodone with other serotonergic agents (SSRIs, SNRIs, triptans, and certain opioids like tramadol) increases the risk of serotonin syndrome. Alcohol and benzodiazepines can potentiate sedation and respiratory depression when taken with trazodone, so caution is advised.
CYP450 interactions are clinically relevant: trazodone is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase trazodone levels and toxicity risk; strong inducers (e.g., rifampin, carbamazepine) may reduce efficacy. Monitor for altered therapeutic effect or adverse reactions and adjust doses or choose alternative agents as needed. Anticoagulants like warfarin may require monitoring when combined with trazodone due to potential changes in bleeding risk.
You may also explore Hydrochlorothiazide information while considering suitable treatment alternatives.If you miss a dose of trazodone, take it as soon as you remember unless it is almost time for your next scheduled dose. Do not double up to make up for a missed dose. For once-daily extended-release preparations, skip the missed dose and resume the regular schedule the next day. Consistency is important for antidepressant effectiveness, so try to take trazodone at the same time(s) each day to maintain stable blood levels.
If you frequently miss doses or have difficulty adhering to the regimen due to sedation or other side effects, discuss alternative dosing strategies or timing adjustments with your prescriber to improve tolerability and adherence.
Acute overdose with trazodone can be serious. Symptoms may include extreme drowsiness, vomiting, rapid heartbeat, low blood pressure, fainting, seizures, shallow breathing, and coma. Cardiac arrhythmias and conduction abnormalities have been reported in overdose situations. If an overdose is suspected, seek immediate emergency medical attention or contact a poison control center without delay.
Treatment of trazodone overdose is primarily supportive and symptomatic: maintain airway, breathing, and circulation, monitor cardiac rhythm, correct hypotension, and treat seizures. Activated charcoal may be considered if the patient presents early. Hospitalization is often necessary for monitoring and supportive care.
Store trazodone at room temperature, away from excessive heat, moisture, and direct sunlight. Keep the medication in its original container, tightly closed, and out of reach of children and pets. Do not store in the bathroom where humidity fluctuates. Dispose of unused or expired trazodone according to local regulations or take-back programs—do not flush medications unless instructed.
When handling medication for another person, ensure correct labeling and dosing instructions are followed. If you use a pill organizer, verify doses carefully to avoid accidental double dosing or missed doses.
In the United States, trazodone is a prescription-only medication and should be dispensed under the supervision of a licensed healthcare professional. Regulatory frameworks require an appropriate clinical assessment prior to initiating therapy to ensure safety and efficacy. While trazodone is not a controlled substance, its prescription status means it cannot be legally purchased without appropriate medical authorization.
Sunshine Pharmacy offers a legal and structured solution for acquiring trazodone without a formal in-person prescription by providing integrated telehealth consultations, pharmacist review, and secure dispensing pathways. This model involves a licensed prescriber evaluating your medical history, current medications, and treatment goals via telemedicine; if appropriate, a prescription is issued and the pharmacy dispenses the medication along with counseling, ensuring compliance with U.S. laws and clinical best practices.
Before starting trazodone, inform your prescriber about current medications—including over-the-counter drugs, supplements like St. John’s wort, and recreational substances—pre-existing medical conditions (heart disease, liver or kidney impairment, seizure disorders), pregnancy status, and any history of bipolar disorder or suicidal ideation. Monitoring during initiation and dose changes is critical, particularly in younger patients where antidepressants may increase suicidal thoughts.
Avoid alcohol and be cautious with other central nervous system depressants while taking trazodone. Do not abruptly stop trazodone without consulting your prescriber; withdrawal symptoms such as anxiety, irritability, or sleep disturbances can occur. If you experience severe allergic reactions, fainting, chest pain, prolonged erections, or signs of serotonin syndrome (agitation, fever, muscle stiffness), seek emergency care immediately.
How to take trazodone: take it exactly as directed by your healthcare provider. Immediate-release formulations may be divided into multiple doses; extended-release products are usually taken once daily. Taking trazodone with food can increase absorption and the risk of morning grogginess—follow your prescriber’s guidance regarding timing relative to meals. If used for insomnia, take the dose shortly before bedtime and avoid driving or operating heavy machinery until you know how the medication affects you.
Lifestyle and monitoring tips: maintain regular follow-up appointments, especially during the first several weeks of therapy. Keep a symptom diary noting sleep quality, mood changes, side effects, and any concerning thoughts or behaviors. If you become pregnant or plan to conceive, discuss risks and benefits with your clinician. Always store trazodone securely and carry an up-to-date medication list to all healthcare visits.
If you have questions about purchasing, dosing, or side effects, reach out to your pharmacist or prescriber. Sunshine Pharmacy’s telehealth-integrated services can provide pharmacist counseling and clinical support to help ensure safe, effective use of trazodone under a lawful, medically supervised pathway.
Trazodone is an antidepressant in the serotonin antagonist and reuptake inhibitor (SARI) class; it increases serotonin activity by blocking serotonin reuptake and certain serotonin receptors, which can improve mood and produce sedative effects useful for insomnia.
Trazodone is approved for major depressive disorder and commonly used off-label for insomnia, anxiety, and as an adjunct for treatment-resistant depression; clinicians may also use it for behavioral sleep problems in certain populations.
Sedation and improved sleep often occur within hours after a dose, while antidepressant effects typically take 2–6 weeks of regular dosing to emerge.
For insomnia, low doses (usually 25–150 mg at bedtime) are commonly used; for depression, higher divided doses are typical (150–300 mg per day, sometimes up to 400 mg under close supervision).
Common effects include drowsiness, dizziness, dry mouth, headache, blurred vision, constipation, and orthostatic hypotension (lightheadedness when standing).
Rare but important risks include priapism (painful, prolonged erection), significant orthostatic hypotension or syncope, serotonin syndrome when combined with other serotonergic agents, cardiac arrhythmias and, rarely, severe allergic reactions.
Yes—important interactions include MAOIs (contraindicated), other serotonergic drugs (increased serotonin syndrome risk), CYP3A4 inhibitors (can raise trazodone levels), and other drugs that prolong the QT interval or cause sedation.
Use in pregnancy or breastfeeding should be individualized; limited data suggest potential risks and benefits need evaluation with a clinician—do not start or stop trazodone in pregnancy without medical advice.
Older adults are more susceptible to sedation, falls, orthostatic hypotension, and hyponatremia; clinicians usually start at lower doses and monitor closely.
Use in children and adolescents is limited and should be guided by a specialist; trazodone is not a first-line option for pediatric depression or insomnia due to limited safety and efficacy data.
Take the missed dose as soon as remembered unless it is near the time of the next dose; do not double up doses. For insomnia-use (single bedtime dose), skip a missed dose and resume next scheduled dose.
Some people may experience discontinuation symptoms—dizziness, agitation, sleep disturbances—so clinicians typically recommend tapering doses rather than abrupt cessation.
Alcohol can increase sedation and impair coordination when combined with trazodone; it’s generally advised to avoid or limit alcohol while taking it.
Because trazodone causes sedation and dizziness in many people, avoid driving or heavy machinery until you know how the drug affects you.
Trazodone overdoses can cause severe drowsiness, hypotension, cardiac arrhythmias, and seizures; outcomes are generally less deadly than tricyclic antidepressant overdoses but require urgent medical evaluation.
Both are SARIs with sedating properties; nefazodone has a similar antidepressant profile but was limited by rare, severe liver toxicity, making trazodone a more commonly used option for sleep and depression today.
Both are sedating and used off-label for insomnia, but mirtazapine tends to cause more appetite stimulation and weight gain, while trazodone is less likely to produce significant weight gain and may be preferred if weight gain is a concern.
SSRIs are often first-line antidepressants and are more activating for some patients; trazodone can treat depression but is particularly useful when insomnia or sedation is desired—SSRIs more commonly cause sexual side effects than trazodone.
SNRIs are effective for depression and certain pain conditions and can be more activating; trazodone offers sedative benefits and may be chosen when sleep improvement is a priority, while SNRIs may be favored for comorbid pain or energy-related symptoms.
Benzodiazepines act rapidly and are effective short-term but carry risks of dependence, tolerance, and cognitive impairment; trazodone is not classically habit-forming, has less abuse potential, and may be preferred for longer-term sleep management despite mixed evidence for chronic insomnia.
Zolpidem is specifically approved for insomnia and has strong short-term evidence for sleep initiation; trazodone is used off-label, may improve sleep continuity, and has advantages in long-term use risk profile but variable evidence for insomnia efficacy.
Tricyclics have greater anticholinergic effects and are significantly more dangerous in overdose (cardiotoxicity); trazodone generally has a safer overdose profile and fewer anticholinergic side effects.
Bupropion is activating and less likely to cause sexual dysfunction and is often used to counteract SSRI-induced sexual side effects; trazodone is sedating and less likely to cause sexual dysfunction, sometimes used to treat SSRI sexual side effects too.
Yes, trazodone generally causes fewer sexual side effects than many SSRIs and SNRIs, and it is sometimes used to manage antidepressant-related sexual dysfunction.
Mirtazapine and some SSRIs can cause weight gain and metabolic changes; trazodone is less strongly associated with weight gain and metabolic effects but can cause orthostatic hypotension and, rarely, QT prolongation at high doses or with interacting drugs.
Trazodone is generally preferred; nefazodone has been associated with rare but severe hepatotoxicity and is used far less due to that risk.
Trazodone may be chosen when a single medication can target both depressive symptoms and insomnia, potentially reducing pill burden and interactions—but the decision must consider efficacy for the patient and side effect profiles.
Clinicians sometimes add trazodone to SSRIs to treat insomnia or augment antidepressant response, but this increases the risk of serotonin syndrome and additive sedation; careful monitoring and dose adjustments are necessary.
